International Urology Cancer Summit’s Post

FDA Approves Subcutaneous Therapy for Solid Tumors! Big news in oncology! The FDA has approved a subcutaneous combo of nivolumab and hyaluronidase for adults with solid tumors like renal cell carcinoma, melanoma, and lung cancer. 💡 Why it’s a breakthrough: Faster: 3-5 min injection vs. IV Effective: Comparable results to IV in trials Versatile: Works as monotherapy or with chemo 📊 Results: In trials with 495 patients, response rates were 24% vs. 18% for IV. Share your thoughts: https://bit.ly/407AEEF #FDAApproval #CancerCare #HealthcareInnovation #docplexus #doctors #mbbs #healthcare #medical #Indiandoctors

Researchers found no significant difference across the three approved CDK4/6 inhibitor treatments for patients with HR+/HER2- mBC in the recently published largest real-world comparative analysis conducted to date. Since 2015, three CDK4/6 inhibitor treatments, palbociclib, ribociclib, and abemaciclib, have been approved for treatment in combination with endocrine therapy, becoming the standard of care for first line treatment of HR+/HER2- mBC. This collaborative research published in ESMO - European Society for Medical Oncology Open used the Flatiron Health EHR-derived panoramic database of >650K patients with breast cancer to provide significant evidence that improves our understanding of treatment options for patients with mBC. Read more on this research and why it matters: https://lnkd.in/eJ9du6ez

#JIPO research article by Nazha et al. explores the effectiveness & safety of treatment for advanced penile squamous cell carcinoma #pSCC using real-world experiences https://lnkd.in/e8pp5DjS #immunotherapy #immunecheckpointinhibitor #nivolumab #pembrolizumab Innovative Oncology Network

In a multicenter, randomized Phase 3 trial, capecitabine and XELOX were found to have similar efficacy to PF in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). Notably, capecitabine demonstrated a lower incidence of severe adverse events compared to PF, suggesting it as a more tolerable alternative. Additionally, consolidation chemotherapy provided a significant survival benefit over DCRT alone. These findings may influence future treatment protocols for ESCC, emphasizing the potential for better patient outcomes with capecitabine-based regimens. #EsophagealCancer #Chemoradiotherapy #OncologyResearch #CancerTreatment #ClinicalTrials

#CARTCELLTHERAPY CAR-T therapy, which the FDA describes as a breakthrough therapy, is expected to be hope for many more patients in the near future. This treatment, which is economically costly, offers an improvement where success rates reach 90% compared to classical treatments. Currently, CAR-T therapy is FDA-approved to treat several types of haematological malignancies, including: -Leukemia. -Lymphoma. -Multiple myeloma. Although current CAR-T therapies have not proven successful in solitary malignacies, studies show that effective products can be developed in solitary malignacies. Clinical trials are being conducted in Glioblastoma, Pontine-Midline glioma, Neuroblastoma and GIS cancer.

Unlock the power of personalized medicine with DiAGSure® KRAS Mutation Detection Kit Detecting KRAS mutations is vital for tailoring cancer treatment strategies. Our kit provides accurate and reliable results, empowering clinicians to make informed decisions for better patient care. Learn more about how our technology is shaping the future of oncology! #KRASmutation #PrecisionMedicine #CancerCare"

We would like to congratulate Rebekah Yu and the co-authors on their manuscript "Real-world study on the characteristics, post-nephrectomy journey, and outcomes of patients with early-stage renal cell carcinoma based on risk groups," a collaboration with Merck that has been published in Cancer Medicine This analysis of medical records from the ConcertAI Oncology Dataset unveiled insights into characteristics, post-nephrectomy outcomes, and patient journeys in the United States. Findings showed promising survival rates for intermediate-high- and high-risk RCC patients, highlighting the potential benefits of new therapeutic options. Read the full manuscript: https://hubs.ly/Q02BLGQw0 #RCCResearch #NephrectomyJourney #CancerOutcomes #MedicalAdvancements

Novocure Announced Positive Topline Results from Phase 3 PANOVA-3 Trial Novocure has reported that the Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The trial evaluated Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment. Novocure plans to advance this treatment toward regulatory review in major global markets. https://lnkd.in/dE7s-YHZ #Cancer #CancerResearch #ClinicalTrial #PancreaticCancer #Medicine #CancerTreatment #CancerDrug #Health #Panova #Oncology #OncoDaily

Research Highlight: In a pharmacokinetic study of 60 people undergoing paclitaxel chemotherapy, the addition of 2 g of plain turmeric daily caused minor reductions in blood drug levels (7.7% less area under the curve and 12.1% less maximum drug concentrations). The observed changes were deemed not clinically relevant using the standard “no effect boundary” of 80%–125%. Link to study: https://lnkd.in/gJi89ede Share to help spread KNOWledge surrounding integrative oncology research! #fyp #integrativeoncology #cancer #naturopathicmedicine #integrativeresearch #knowoncology #oncanp #breastcancer 

In this article we proposed PD-L1 may be used as a prognostic biomarker in the diagnosis, treatment, and management of pancreatic cancer patients.